- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03550768
Effect of Anatomy of Major Duodenal Papilla on the Difficulty of Cannulation During Endoscopic Retrograde Cholangiopancreatography
December 24, 2019 updated by: Yanglin Pan, Air Force Military Medical University, China
Effect of Anatomy of Major Duodenal Papilla on the Difficulty of Cannulation During Endoscopic Retrograde Cholangiopancreatography (ERCP)
Selective cannulation is an essential step for the success of ERCP.
The successful cannulation is influenced by types of disease (such as Sphincter of Oddi Dysfunction and duodenal stricture), the experience of endoscopists and the anatomy of papilla.
It is suggested that the size, morphology, orientation and location of major duodenal papilla (MDP), could cause a difficult cannulation (Endoscopy 2016; 48: 657-683).
However, the related evidences are limited.
The investigators hypothesized that special anatomy of papilla, such as a lanky shape (defined by the higher ratio of length to width) and a deeper location, could increase the difficulty of cannulation.
Here the investigators investigated the effects of the anatomy of major duodenal papilla on post-ERCP pancreatitis and the procedure of cannulation in patients undergoing ERCP.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
658
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chongqing, China, 400010
- Department of gastroenterology, Second Affiliated Hospital of Chongqing Medical University
-
-
Fujian
-
Xiamen, Fujian, China, 361001
- Department of gastroenterology, Successful Hospital of Xiamen university
-
-
Henan
-
Kaifeng, Henan, China, 475000
- Huaihe Hospital of Henan University
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Endoscopic center, Xijing Hospital of Digestive Diseases
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with native papilla who underwent ERCP
Description
Inclusion Criteria:
- age 18-80
- Patients with native papilla who underwent ERCP
Exclusion Criteria:
- Prior endoscopic sphincterotomy
- Minor pancreatic duct as the targeted duct
- History of prior upper gastrointestinal surgery, such as Billroth I, II and Roux-en-Y
- Fistula of MDP
- Papillary carcinoma or adenoma
- Duodenal obstruction, type II
- Prior stent placement in common bile duct or pancreatic duct
- Pregnant or breastfeeding women
- Unwilling or inability to provide consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
MDP
ERCP was performed by trainees or trainers.
Before the cannulation, the photo of major duodenal papilla will be taken carefully to evaluate its size, morphology, orientation and location.
All patients initially received wire-guided cannulation with a sphincterotome, If cannulation failed, precut sphincterotomy or the double-wire technique was performed when appropriate.
Therapeutic manipulation (eg, sphincterotomy, balloon dilation, stone extraction, and stenting) was done when appropriate.
Pancreatic duct stent placement was performed at the discretion of the endoscopists.
|
evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
post-ERCP pancreatitis incidence
Time Frame: 48 hours
|
frequency of post-ERCP pancreatitis
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of difficult cannulation
Time Frame: 3 hours
|
difficult cannulation was defined as when total cannulation time was more than 5minutes, total cannulation attempts more than 5 times or inadvertent pancreatic duct cannulation more than 1 time.
|
3 hours
|
|
Cannulation attempts
Time Frame: 3 hours
|
the sphincterotome touching the papilla for at least 5 seconds will be considered as one attempt.
|
3 hours
|
|
Total cannulation time
Time Frame: 3 hours
|
the time from the moment the sphincterotome touch the papilla to the guide wire advance into the target duct.
|
3 hours
|
|
Unintended pancreatic duct cannulation
Time Frame: 3 hours
|
the guide wire unintentionally entered into the undesired pancreatic duct
|
3 hours
|
|
Complication rate
Time Frame: 48 hours
|
frequency of any adverse outcome that required hospital admission or prolonged hospital stay necessary for management of the complication, including pancreatitis, bleeding, biliary infection or perforation.
|
48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2018
Primary Completion (Actual)
April 20, 2019
Study Completion (Actual)
April 30, 2019
Study Registration Dates
First Submitted
May 16, 2018
First Submitted That Met QC Criteria
June 7, 2018
First Posted (Actual)
June 8, 2018
Study Record Updates
Last Update Posted (Actual)
December 26, 2019
Last Update Submitted That Met QC Criteria
December 24, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- KY20180081-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endoscopic Retrograde Cholangiopancreatography
-
Beijing Friendship HospitalCompletedEndoscopic Retrograde CholangiopancreatographyChina
-
Indiana UniversityCompletedCholangiopancreatography, Endoscopic RetrogradeUnited States
-
Boston Scientific CorporationCompletedEndoscopic Retrograde CholangiopancreatographyUnited States, Netherlands
-
Helsinki University Central HospitalCompletedEndoscopic Retrograde CholangiopancreatographyFinland
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingEndoscopic Retrograde CholangiopancreatographyItaly
-
Kliniken Ludwigsburg-Bietigheim gGmbHNot yet recruitingCholangiopancreatography, Endoscopic Retrograde
-
Olympus Europe SE & Co. KGCompletedCholangiopancreatography, Endoscopic RetrogradeBelgium, Germany, Norway
-
Boston Scientific CorporationCompletedEndoscopic Retrograde CholangiopancreatographyUnited States
-
Helsinki University Central HospitalTurku University Hospital; Oulu University HospitalCompletedEndoscopic Retrograde CholangiopancreatographyFinland
-
University Hospital, LinkoepingCompletedEndoscopic Retrograde CholangiopancreatographySweden
Clinical Trials on MDP
-
Association pour le Développement et l'Organisation...Not yet recruitingDyspnea | Congenital Central Hypoventilation Syndrome | CCHSFrance
-
Institut für Pneumologie Hagen Ambrock eVActive, not recruitingOSA | COPD | COPD Exacerbation | CHFGermany
-
University of East AngliaCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingDyspnea and Respiratory Insufficiency in ChildrenFrance
-
Medhat OsmanBlue Earth DiagnosticsCompleted
-
Kafrelsheikh UniversityCompletedEndodontically Treated Teeth | Anterior TeethEgypt
-
Assiut UniversityNot yet recruitingBone Metastases | Urogenital Cancer
-
American College of Radiology - Image MetrixWorld Molecular Imaging SocietyUnknownBone MetastasesUnited States, Australia, Austria, Portugal, Switzerland
-
Mohamed FathyUnknownLow Back Pain, Mechanical
-
Valentina GaribottoUniversity Hospital, GenevaCompletedProstate Cancer | Bone MetastasesSwitzerland